Astrazeneca Ab

Andrew George Brewster

Frederic H Jung

Andrew Mortlock

Nicholas John Keen

The use of a compound of formula (I) or a salt, ester, amide or prodrug thereof; where X is O, or S, S(O) or S(O), NH or NRwhere Ris hydrogen or Calkyl; Ris selected from a group NHC(O)OR, NHC(O)R, NHS(O)R, C(O)R, C(O)OR, S(O)R, S(O)OR, S(O)OR, C(O)NRR, S(O)NRRS(O)ONRR, where R, Ror Rare various specified organic groups; Ris hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl; Rand Rare various specified organic groups, and R, R, R, Rare independently selected from halogeno, cyano, nitro, Calkylsulphanyl, &#x2014;N(OH)R&#x2014; (wherein Ris hydrogen, or Calkyl), or RX&#x2014; (wherein Xrepresents a direct bond, &#x2014;O&#x2014;, &#x2014;CH&#x2014;, &#x2014;OCO&#x2014;, carbonyl, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, &#x2014;SO&#x2014;, &#x2014;NRCO&#x2014;, &#x2014;CONR&#x2014;, &#x2014;SONR&#x2014;, &#x2014;NRSO&#x2014; or &#x2014;NR&#x2014; (wherein R, Rand Reach independently represents hydrogen, Calkyl or Calkoxy Calkyl), and Ris hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy; in the preparation of a medicament for use in the inhibition of aurora 2 kinase. 

Growing community of inventors

Paris, France

Andrew George Brewster